Literature DB >> 22250216

Biophysical characterization of M1476I, a sodium channel founder mutation associated with cold-induced myotonia in French Canadians.

Juan Zhao1, Nicolas Duprè, Jack Puymirat, Mohamed Chahine.   

Abstract

M1476I, a French Canadian founder mutation of Na⁺ channel Nav1.4, causes potassium-aggravated myotonia, with cold-induced myotonia as the most distinctive clinical feature. Mexiletine, a class 1B local anaesthetic, relieves the myotonic symptoms of patients carrying the M1476I mutation. We used the patch-clamp method to investigate the functional characteristics of this mutation by heterologous expression in tsA201 cells. The M1476I mutation caused an increased persistent Na⁺ current, a 2- to 3-fold slower fast inactivation, a 6.4 mV depolarizing shift in the midpoint of steady-state inactivation, and an accelerated recovery from fast inactivation compared to the wild-type (WT) channel. Cooling slowed the kinetics of both channel types and increased the amplitude of the persistent current in M1476I channels.Mexiletine suppressed the persistent Na⁺ current generated by the M1476I mutation and blocked both WT and M1476I channels in a use- dependent manner. The inactivation-deficient M1476I channels were less susceptible to mexiletine during repetitive pulses. The decreased use-dependent block of M1476I channels might have resulted from the slower onset of mexiletine block, and/or the faster recovery from mexiletine block, given that the affinity of mexiletine for the inactivated state of the WT and mutant channels was similar. Increased extracellular concentrations of potassium had no effect on either M1476I or WT currents. These results indicated that cooling can augment the disruption of the voltage dependence of fast inactivation by M1476I channels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22250216      PMCID: PMC3424721          DOI: 10.1113/jphysiol.2011.223461

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  43 in total

1.  Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.

Authors:  Hai Huang; Silvia G Priori; Carlo Napolitano; Michael E O'Leary; Mohamed Chahine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

2.  Myotonic disorders.

Authors:  Frank Lehmann-Horn; Karin Jurkat-Rott
Journal:  Handb Clin Neurol       Date:  2007

3.  Impaired slow inactivation in mutant sodium channels.

Authors:  T R Cummins; F J Sigworth
Journal:  Biophys J       Date:  1996-07       Impact factor: 4.033

4.  Effect of temperature and ouabain on th Na+--K+ activated membrane ATPase and electrogenic ionic pump of the golden hamster and mouse diaphragm.

Authors:  H Dlouhá; Y Donselaar; J Teisinger; F Vyskocil
Journal:  Physiol Bohemoslov       Date:  1980

Review 5.  Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses.

Authors:  S C Cannon
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

6.  A novel founder SCN4A mutation causes painful cold-induced myotonia in French-Canadians.

Authors:  E Rossignol; J Mathieu; I Thiffault; M Tétreault; M-J Dicaire; N Chrestian; N Dupré; J Puymirat; B Brais
Journal:  Neurology       Date:  2007-11-13       Impact factor: 9.910

7.  Cold-induced disruption of Na+ channel slow inactivation underlies paralysis in highly thermosensitive paramyotonia.

Authors:  Thomas Carle; Emmanuel Fournier; Damien Sternberg; Bertrand Fontaine; Nacira Tabti
Journal:  J Physiol       Date:  2009-02-16       Impact factor: 5.182

8.  Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH.

Authors:  F Lehmann-Horn; G Küther; K Ricker; P Grafe; K Ballanyi; R Rüdel
Journal:  Muscle Nerve       Date:  1987-05       Impact factor: 3.217

9.  Paramyotonia congenita: the R1448P Na+ channel mutation in adult human skeletal muscle.

Authors:  H Lerche; N Mitrovic; V Dubowitz; F Lehmann-Horn
Journal:  Ann Neurol       Date:  1996-05       Impact factor: 10.422

Review 10.  Overview of the voltage-gated sodium channel family.

Authors:  Frank H Yu; William A Catterall
Journal:  Genome Biol       Date:  2003-02-24       Impact factor: 13.583

View more
  7 in total

1.  Keeping hyperactive voltage-gated sodium channels in silent mode.

Authors:  Saïd Bendahhou
Journal:  J Physiol       Date:  2012-06-01       Impact factor: 5.182

Review 2.  Sodium channels and pain: from toxins to therapies.

Authors:  Fernanda C Cardoso; Richard J Lewis
Journal:  Br J Pharmacol       Date:  2017-09-02       Impact factor: 8.739

3.  Modulatory features of the novel spider toxin μ-TRTX-Df1a isolated from the venom of the spider Davus fasciatus.

Authors:  Fernanda C Cardoso; Zoltan Dekan; Jennifer J Smith; Jennifer R Deuis; Irina Vetter; Volker Herzig; Paul F Alewood; Glenn F King; Richard J Lewis
Journal:  Br J Pharmacol       Date:  2017-06-27       Impact factor: 8.739

4.  Mexiletine for treatment of myotonia: a trial triumph for rare disease networks.

Authors:  Eric P Hoffman; Henry J Kaminski
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

5.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

6.  Rapid evolution of a voltage-gated sodium channel gene in a lineage of electric fish leads to a persistent sodium current.

Authors:  Ammon Thompson; Daniel T Infield; Adam R Smith; G Troy Smith; Christopher A Ahern; Harold H Zakon
Journal:  PLoS Biol       Date:  2018-03-27       Impact factor: 8.029

7.  Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.

Authors:  R Cregg; J J Cox; D L H Bennett; J N Wood; R Werdehausen
Journal:  Br J Pharmacol       Date:  2014-08-29       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.